RecruitingEarly Phase 1NCT07337434

To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital

Comparison of Efficacy of Methotrexate vs Apremilast in Moderate to Severe Plaque Psoriasis

Sponsor

Syeda Sana Zaman

Enrollment

106 participants

Start Date

Dec 25, 2025

Study Type

INTERVENTIONAL

Summary

This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria1

Patients having age between 18-60 years of either gender Diagnosed with moderate to severe plaque psoriasis (PASI ≥10) No prior systemic therapy in past 3 months.

Exclusion Criteria1

Pregnancy or lactation History of liver or renal dysfunction Known hypersensitivity to study drugs

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethotrexate

Group A will recieve methotrexate 10-25mg once weekly for 3 months. Along with folic acid once daily except on day of methotrexate.

DRUGApremilast

Group B will recieve tablet apremilast 30mg twice daily for 3 months.

Locations(1)

MTI-HMC Peshawar

Peshawar, Khyber Pukhtunkhwa, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07337434